157 related articles for article (PubMed ID: 25972501)
1. Starter packs versus full prescription of antiretroviral drugs for postexposure prophylaxis: a systematic review.
Ford N; Venter F; Irvine C; Beanland RL; Shubber Z
Clin Infect Dis; 2015 Jun; 60 Suppl 3():S182-6. PubMed ID: 25972501
[TBL] [Abstract][Full Text] [Related]
2. Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review.
Ford N; Shubber Z; Calmy A; Irvine C; Rapparini C; Ajose O; Beanland RL; Vitoria M; Doherty M; Mayer KH
Clin Infect Dis; 2015 Jun; 60 Suppl 3():S170-6. PubMed ID: 25972499
[TBL] [Abstract][Full Text] [Related]
3. Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis.
Ford N; Irvine C; Shubber Z; Baggaley R; Beanland R; Vitoria M; Doherty M; Mills EJ; Calmy A
AIDS; 2014 Nov; 28(18):2721-7. PubMed ID: 25493598
[TBL] [Abstract][Full Text] [Related]
4. Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review.
Penazzato M; Dominguez K; Cotton M; Barlow-Mosha L; Ford N
Clin Infect Dis; 2015 Jun; 60 Suppl 3():S177-81. PubMed ID: 25972500
[TBL] [Abstract][Full Text] [Related]
5. HIV Postexposure Prophylaxis Starter Packs Were Not Designed to Help or Hinder Adherence.
Zimmer R
Clin Infect Dis; 2016 Mar; 62(5):667-8. PubMed ID: 26582746
[No Abstract] [Full Text] [Related]
6. Prescribing practices in a population-based HIV postexposure prophylaxis program.
Braitstein P; Chan K; Beardsell A; McLeod A; Montaner JS; O'Shaughnessy MV; Hogg RS
AIDS; 2002 May; 16(7):1067-70. PubMed ID: 11953474
[TBL] [Abstract][Full Text] [Related]
7. Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men.
Foster R; McAllister J; Read TR; Pierce AB; Richardson R; McNulty A; Carr A
Clin Infect Dis; 2015 Oct; 61(8):1336-41. PubMed ID: 26123937
[TBL] [Abstract][Full Text] [Related]
8. World Health Organization Guidelines on Postexposure Prophylaxis for HIV: Recommendations for a Public Health Approach.
Ford N; Mayer KH;
Clin Infect Dis; 2015 Jun; 60 Suppl 3():S161-4. PubMed ID: 25972497
[TBL] [Abstract][Full Text] [Related]
9. Network meta-analysis of post-exposure prophylaxis randomized clinical trials.
Fernández I; de Lazzari E; Inciarte A; Diaz-Brito V; Milinkovic A; Arenas-Pinto A; Etcheverrry F; García F; Leal L;
HIV Med; 2021 Mar; 22(3):218-224. PubMed ID: 33108035
[TBL] [Abstract][Full Text] [Related]
10. The use of HIV post-exposure prophylaxis in forensic medicine following incidents of sexual violence in Hamburg, Germany: a retrospective study.
Ebert J; Sperhake JP; Degen O; Schröder AS
Forensic Sci Med Pathol; 2018 Sep; 14(3):332-341. PubMed ID: 29777425
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of HIV Postexposure Prophylaxis: Systematic Review and Meta-analysis of Nonhuman Primate Studies.
Irvine C; Egan KJ; Shubber Z; Van Rompay KK; Beanland RL; Ford N
Clin Infect Dis; 2015 Jun; 60 Suppl 3():S165-9. PubMed ID: 25972498
[TBL] [Abstract][Full Text] [Related]
12. Single-tablet regimen of emtricitabine/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims.
Malinverni S; Bédoret F; Bartiaux M; Gilles C; De Wit S; Libois A
Sex Transm Infect; 2021 Aug; 97(5):329-333. PubMed ID: 33106437
[TBL] [Abstract][Full Text] [Related]
13. Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.
Mayer KH; Jones D; Oldenburg C; Jain S; Gelman M; Zaslow S; Grasso C; Mimiaga MJ
J Acquir Immune Defic Syndr; 2017 Aug; 75(5):535-539. PubMed ID: 28696345
[TBL] [Abstract][Full Text] [Related]
14. Adherence to HIV post-exposure prophylaxis for children/adolescents who have been sexually assaulted: A systematic review of barriers, enablers, and interventions.
Shubber Z; Ford N
Child Abuse Negl; 2021 Jun; 116(Pt 1):104143. PubMed ID: 31522763
[TBL] [Abstract][Full Text] [Related]
15. Significant intolerability of efavirenz in HIV occupational postexposure prophylaxis.
Wiboonchutikul S; Thientong V; Suttha P; Kowadisaiburana B; Manosuthi W
J Hosp Infect; 2016 Apr; 92(4):372-7. PubMed ID: 26876748
[TBL] [Abstract][Full Text] [Related]
16. Telephone delivered interventions for preventing HIV infection in HIV-negative persons.
van-Velthoven MH; Tudor Car L; Gentry S; Car J
Cochrane Database Syst Rev; 2013 May; (5):CD009190. PubMed ID: 23728688
[TBL] [Abstract][Full Text] [Related]
17. Formulating the Future Research Agenda for Postexposure Prophylaxis for HIV: Methodological Challenges and Potential Approaches.
Siegfried N; Beanland RL; Ford N; Mayer KH
Clin Infect Dis; 2015 Jun; 60 Suppl 3():S205-11. PubMed ID: 25972506
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
Inciarte A; Leal L; González E; León A; Lucero C; Mallolas J; Torres B; Laguno M; Rojas J; Martínez-Rebollar M; González-Cordón A; Cruceta A; Arnaiz JA; Gatell JM; García F;
J Antimicrob Chemother; 2017 Oct; 72(10):2857-2861. PubMed ID: 29091217
[TBL] [Abstract][Full Text] [Related]
19. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis.
Kuhar DT; Henderson DK; Struble KA; Heneine W; Thomas V; Cheever LW; Gomaa A; Panlilio AL;
Infect Control Hosp Epidemiol; 2013 Sep; 34(9):875-92. PubMed ID: 23917901
[TBL] [Abstract][Full Text] [Related]
20. Pre-elective HIV postexposure prophylaxis clinic for medical students: design, protocol, uptake and effectiveness.
Stacey K; Sellers L; Barrett S
Int J STD AIDS; 2012 Sep; 23(9):667-9. PubMed ID: 23033524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
